Should the exclusivity period for biosimilars shorten?

This week, 51 of the members of the House of Representatives asked President Obama not to shorten the exclusivity period of biosimilars from 12 years to seven as a part of the Affordable Care Act.  His latest plan for economic growth and debt reduction, branded biosimilars producers would face the shortened exclusivity time.  The House of Representatives believes that biosimilars can be a great asset to the market and patients who face the high prices of biologic drugs.  Patient Docs believes that the ultimate losers in this potential situation are the patients. Many companies would look to move abroad where they were in an atmosphere that supported and acknowledged the importance of innovation, leaving America because of no incentive to develop these cheaper drugs.

What do you think about the exclusivity period?  Should it be seven or twelve years, and how does each scenario affect the American people?

Share this article with your social network, just click below to share now!

Share |

Hear from leading experts in biotech and biosimilar legislation

This fall, the Business of Biosimilars event addresses the key legal issues surrounding this new marketplace with insight into:

* Data and market exclusivity periods
* IP/Patent protection for biologics and next generation biologics
* Methods for resolving disputes between innovator and imitator applicants
* Global case studies highlighting the outcome of patent settlements
* Analysis of the current competitive landscape

Don’t miss your opportunity to collaborate with the leading experts in biotech and biosimilar legislation:
Michael S. Wroblewski, Bureau of Competition, The Federal Trade Commission
Bruce Leicher, SVP and General Council, Momenta Pharmaceuticals, Inc.
Mark Bowditch, Patent Attorney, Sandoz
Naomi Pearce, Director, Biosimilars IP, Hospira
Aaron F. Barkoff, PhD, Author, The Orange Book Blog, Patent Attorney, MBHB

And that’s just the beginning. To view the complete speaker line-up and event program click here!

Register today and secure your spot at the biosimilars event of the year.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |